

Index

A

AB-729, 118
ABI-H0731, 118
Adefovir, 113
Adolescents, 1
Adults, 39
Aflatoxins, 2, 57
AJCC Cancer Staging Manual, 77
Alagille syndrome, 4
Alpha-1-antitrypsin deficiency, 17
Antiviral, 113, 116, 117
ARC-520, 117
Autoimmune hepatitis, 4

B

Barcelona Clinic Liver Cancer score, 8
BCLC staging system, 49
Besifovir dipivoxil maleate, 118
Bevacizumab, 10
Biliary atresia, 3
Biliary lesions, 96
Bridging therapy, 127, 130
Budd-Chiari syndrome, 4

C

Cabozantinib, 10
Capecitabine, 10
Capsid inhibitors, 118
Carcinoma of the Liver, 1
Cavernous hemangioma, 99
cccDNA inhibitors, 119
CD34, 46

Checkpoint inhibitors, 120
Children, 1
Children's Cancer Study Group
 Staging, 152
Children's Oncology Group, 8
Cholangiocarcinoma, 21, 97
Cisplatin, 10
Clinical characteristics, 43
CLIP staging systems, 48
Congenital biliary dilatation, 22
Congenital portosystemic shunts, 3
Core protein inhibitor, 119
Couinaud segments, 79
Cryoablation, 65
Cure, 109

D

Diagnostic tests, 43
Diagnostics, 148
Diet, 70
Differential diagnosis, 6, 23, 171
Downstaging, 127, 129, 130
Doxorubicin, 10
Drug targets, 111
Ductal plate malformation, 22

E

Electron microscopy, 168
Entecavir, 113, 119
Entry inhibitors, 115
Epidemiology, 57, 147
Epithelioid hemangioendothelioma, 100

Erlotinib, 10
Etiology, 40, 146
Everolimus, 10
Expanded criteria, 127, 129

F

Fibrolamellar carcinoma, 13
Fluorouracil (5FU), 10
Focal nodular hyperplasia, 11, 89
Follow-up, 11, 157
Fresh tissue, 81

G

Gemcitabine, 10
Global estimates, 57
Glycogen storage disorders, 20
Glypican-3, 46
Gross anatomy, 78
Gross dissection, 77
Gross features, 167
Gross inspection, 81

H

HBsAg inhibitors, 119
HBV life cycle, 111
Hematoxylin and eosin stain, 42
Hepatic angiosarcoma, 102
Hepatitis B, 109
Hepatoblastoma, 145
Hepatocellular adenoma, 11, 91
Hepatocellular carcinoma, 2, 39, 93
Hepatocellular lesions, 89
Hereditary tyrosinemia I, 19
Histology, 149, 167
Host immunity, 120

I

Ifosfamide, 10
Imaging, 5, 148
Immunohistochemistry, 168
Immunopathogenesis, 111
Immunotherapy, 70
International Society of Pediatric
Oncology, 8
Irinotecan, 10
Irreversible electroporation, 68

J

JAG-1, 4
JAGGED-1, 4
JNJ-3989, 118

K

Keratin, 13, 16
Kidney, 7, 23, 80

L

Laboratory tests, 148
Lamivudine, 113
Lifestyle, 70
Lipid conjugates, 118
Lipid-rich hepatocellular
carcinoma, 13
Liver lesions, 88
Liver resection, 63
Liver transplantation, 63, 129, 155
Liver tumors, 2, 87
Locoregional therapies, 127, 131
Lung metastases, 156
Lymph nodes, 83

M

Management, 62
Metastatic malignancies, 103
Micrographs, 7
Microwave ablation, 65
Milan criteria, 64, 129
Mitomycin, 10
Molecular findings, 170
Morphology, 6
Mucinous cystic neoplasm, 97

N

Natural history, 112
Non-alcoholic fatty liver disease, 55
Non-alcoholic steatohepatitis, 55
Nucleos(t)ide analogues, 109

O

Okuda system, 8, 48
Oxaliplatin, 10

P

Pathogenesis, 40, 146
Pediatric metabolic conditions, 17
Pegylated interferon, 113
Percutaneous ethanol injection, 64
Pregenomic RNA (pgRNA), 112
Pre-neoplastic lesions, 41
PRETEXT, 8, 152
Prevention, 113, 114
Primary liver cancer, 55
Prognosis, 170
Progressive familial intrahepatic cholestasis
type, 2, 20

Q

Quadrant, 78
Quadrat lobe, 79

R

Radiofrequency ablation, 64
Radiologic-pathologic correlation, 87
Radiology, 89, 166
Reticulin stain, 43
Reverse transcriptase inhibitors, 118
Risk assessment, 152

S

Sampling, 81, 83
Sarcoma of the liver, 165
Sarcomas, 175
Selection criteria for liver
transplantation, 129
Small interfering RNAs, 117
Sorafenib, 10
Staging, 8, 47, 61, 83, 151
Stereotactic body radiation therapy, 137
Stereotactic body radiotherapy, 68
Surface inspection, 78
Surgical anatomy of the liver, 78
Surgical approach, 154
Symptoms, 5, 147
Systemic therapies, 69

T

Targeted therapies, 69
Telbivudine, 113
Temozolomide, 10
Tenofovir alafenamide, 113

Tenofovir disoproxil fumarate, 113
Therapeutic considerations, 151
Therapy planning, 152
Thermal ablation, 136
Time of surgical procedure, 153
Tivantinib, 10
TNM classification, 47
Trans-arterial chemoembolization,
66, 131
Transcatheter arterial
radioembolization, 134
Treatment of relapses, 157
Treatment, 8, 49, 62, 109, 113, 170
Treatment-response, 111
Tumor biology, 131
Tumor node metastasis, 8
Tumor, 82

U

Undifferentiated embryonal sarcoma
of the liver, 165
UNOS criteria, 129

V

Vascular endothelial growth factor, 10
Vascular mesenchymal lesions, 99
Vincristine, 10

W

Wilson's disease, 21
Wnt/ β -Catenin, 112

X

X-ray imaging, 14

Y

Y-90 radioembolization, 67

Z

Z allele, 17
Zellballen growth pattern, 16
Zinc finger nucleases, 119
Zonal, 7

Doi: <https://doi.org/10.36255/exonpublications.livercancer.2021.index>